fbpx
Wikipedia

Favipiravir

April 11, 2024

Favipiravir, sold under the brand name Avigan among others,[3] is an antiviral medication used to treat influenza in Japan.[4] It is also being studied to treat a number of other viral infections, including SARS-CoV-2.[4] Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.[5]

Favipiravir
Clinical data
Trade namesAvigan (アビガン, Abigan), Avifavir,[1] Areplivir,[2] others
Other namesT-705, favipira, favilavir
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 6-fluoro-3-hydroxypyrazine-2-carboxamide
CAS Number
  • 259793-96-9
PubChem CID
  • 492405
DrugBank
  • DB12466
ChemSpider
  • 431002
UNII
  • EW5GL2X7E0
KEGG
  • D09537
ChEBI
  • CHEBI:134722
ChEMBL
  • ChEMBL221722
CompTox Dashboard (EPA)
  • DTXSID60948878
Chemical and physical data
FormulaC5H4FN3O2
Molar mass157.104 g·mol−1
3D model (JSmol)
  • Interactive image
  • C1=C(N=C(C(=O)N1)C(=O)N)F
  • InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
  • Key:ZCGNOVWYSGBHAU-UHFFFAOYSA-N

It is being developed and manufactured by Toyama Chemical (a subsidiary of Fujifilm) and was approved for medical use in Japan in 2014.[6] In 2016, Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Co.[7] It became a generic drug in 2019.[citation needed]

Medical use edit

Favipiravir has been approved to treat influenza in Japan.[6] It is, however, only indicated for novel influenza (strains that cause more severe disease) rather than seasonal influenza.[6][8] As of 2020, the probability of resistance developing appears low.[6]

Side effects edit

There is evidence that use during pregnancy may result in harm to the baby.[6] Teratogenic and embryotoxic effects were shown on four animal species.[6][9] In one case report, a 6-month old infant developed benign bright blue discolouration of the cornea after treatment with favipiravir which resolved after treatment cessation.[10]

Mechanism of action edit

The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase.[11][medical citation needed] Favipiravir is a prodrug that is metabolized to its active form, favipiravir-ribofuranosyl-5'-triphosphate (favipiravir-RTP), available in both oral and intravenous formulations.[12][13] In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.[14] However, favipiravir has not been shown to be effective in primary human airway cells, casting doubt on its efficacy in influenza treatment.[15]

 
Favipiravir ribofuranosyl triphosphate, the active form inside the body

Favipiravir-RTP is a nucleoside analogue. It mimics both guanosine and adenosine for the viral RdRP. Incorporating two such bases in a row stops primer extension, although it is unclear how as of 2013.[11]

Society and culture edit

Legal status edit

The US Department of Defense developed favipiravir in partnership with MediVector, Inc. as a broad-spectrum antiviral and sponsored it through FDA Phase II and Phase III clinical trials, where it demonstrated safety in humans and efficacy against the influenza virus.[16] favipiravir remains unapproved in the UK and the USA.[17] In 2014, Japan approved favipiravir for treating influenza strains unresponsive to current antivirals.[18] Toyama Chemical initially hoped that favipiravir would become a new influenza medication that could replace oseltamivir (brand name Tamiflu). However, animal experiments show the potential for teratogenic effects, and the approval of production by The Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.[19]

Despite limited data on efficacy, as of March 2021 favipiravir is widely prescribed for outpatient treatment of mild to moderate COVID-19 in Egypt,[20] Hungary[21] and Serbia.[22] Patients are required to sign a consent form before obtaining the drug.[citation needed]

Brand names edit

 
Favipiravir 800 mg tablets from India

Favipiravir is sold under the brand names Avigan (アビガン, Abigan), Avifavir,[1] Avipiravir,[23] Areplivir,[2] FabiFlu,[24] Favipira,[25] Reeqonus,[26][27] and Qifenda.

Use in Russia edit

Coronavir is the brand name of favipiravir used in Russia, where it is approved for the treatment of COVID-19. It is produced and sold by R-Pharm.[28][29] Coronavir was approved for use in Russia in hospitals in July 2020, and in September 2020 it received approval for prescription sales for outpatient use.[30]

Research edit

COVID-19 edit

See also: Coronavirus disease 2019 § Research, and COVID-19 drug repurposing research § Favipiravir

Favipiravir, as an antiviral drug, has been authorized for treating COVID-19 in several countries including Japan, Russia, Serbia, Turkey, India, and Thailand, under emergency provisions.[31][32][33][34] A rapid meta-review in September 2020 (analyzing four studies) noted that the drug led to clinical and radiological improvements; however, no reduction in mortality or differences in oxygen-support requirement were observed and more rigorous studies were sought.[35][36] A Cochrane Systematic review published in Feb 2024, noted that there is actually no real benefit with Favipiravir in treating Covid-19 in terms of mortality benefits, or admission to mechanical ventillation, or hospitalisation, and it may not make any difference in adverse effects or serious adverse effects.[37]

As of May 2021, large-cohort clinical trials are underway.[38]

Ebola edit

Research in 2014, suggested that favipiravir may have efficacy against Ebola based on studies in mouse models; efficacy in humans was unaddressed.[39][40][41]

During the 2014 West Africa Ebola virus outbreak, a French nurse who contracted Ebola while volunteering for Médecins Sans Frontières (MSF) in Liberia reportedly recovered after receiving a course of favipiravir.[42] A clinical trial investigating the use of favipiravir against Ebola virus disease began in Guéckédou, Guinea, in December 2014.[43] Preliminary results presented in 2016 at the Conference on Retroviruses and Opportunistic Infections (CROI), later published, showed a decrease in mortality in patients with low-to-moderate levels of virus in blood, but no effect on patients with high levels (the group at a higher risk of death).[44][45][46] The trial design was concomitantly criticised for using only historical controls.[47]

Nipah edit

Nipah virus is a causative agent of outbreaks of encephalitis with pneumonia and has a high case fatality rate. The first outbreak occurred in Malaysia-Singapore, related to contact with pigs in slaughterhouses and an outbreak in Philippines related to slaughter of horses, most other outbreaks have affected India and Bangladesh. in Bangladesh outbreaks are often associated with consumption of raw date palm sap contaminated by saliva and urine of fruit bats.[48] In a study published in the Scientific Reports, Syrian hamster model for Nipah virus infection was used, which closely mirrors most aspects of human disease, such as widespread vasculitis, pneumonia, and encephalitis. The hamsters were infected with a lethal dose of 104 PFU NiV-M via the intraperitoneal (i.p.) route similar to previous studies and treatment was initiated immediately after infection. Favipiravir was administered twice daily via the peroral (p.o.) route for 14 days. The treated hamsters displayed 100% survival and no obvious morbidity after lethal NiV challenge, whereas all the control cases died of severe disease.[49]

Other edit

In experiments in animals favipiravir has shown activity against West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses.[50] Activity against enteroviruses[51] and Rift Valley fever virus has also been demonstrated.[52] Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608.[53] The agent has also shown some efficacy against rabies,[54] and has been used experimentally in some humans infected with the virus.[55]

Tautomerism edit

The possible tautomerism of favipiravir has been investigated computationally[56] and experimentally.[57] It was found that the enol-like form was substantially more stable in organic solvents than the keto-like form, meaning that Favipiravir likely exists almost exclusively in the enol-like form. In aqueous solution the keto-like tautomer is substantially stabilized due to the specific interaction with the water molecules. Upon protonation the keto form is switched on.[citation needed]

  •  
    Enol-like tautomeric form
  •  
    Keto-like tautomeric form

References edit

  1. ^ a b "Avifavir". Russian drug reference. Medum.ru.
  2. ^ a b "Arelpivir". Russian drug reference. Medum.ru.
  3. ^ "Glenmark launches Covid-19 drug FabiFlu, priced at Rs 103 per tablet". Business Standard India. Press Trust of India. 20 June 2020.
  4. ^ a b Du YX, Chen XP (August 2020). "Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection". Clinical Pharmacology and Therapeutics. 108 (2): 242–247. doi:10.1002/cpt.1844. PMID 32246834.
  5. ^ Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. (June 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research. 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMC 7127082. PMID 19428599.
  6. ^ a b c d e f Shiraki K, Daikoku T (May 2020). "Favipiravir, an anti-influenza drug against life-threatening RNA virus infections". Pharmacology & Therapeutics. 209: 107512. doi:10.1016/j.pharmthera.2020.107512. PMC 7102570. PMID 32097670.
  7. ^ EJ Lane (22 June 2016). "Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals". Fierce Pharma. Retrieved 20 April 2020.
  8. ^ "Information of Avigan Tablet in relation to Covid-19". FUJIFILM Toyama Chemical Co., Ltd.
  9. ^ Pilkington V, Pepperrell T, Hill A (April 2020). "A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?". Journal of Virus Eradication. 6 (2): 45–51. doi:10.1016/S2055-6640(20)30016-9. PMC 7331506. PMID 32405421.
  10. ^ Jiravisitkul P, Thonginnetra S, Wongvisavavit R (2023). "Case report: Favipiravir-induced bluish corneal discoloration in infant with COVID-19". Frontiers in Pediatrics. 11: 1154814. doi:10.3389/fped.2023.1154814. PMC 10154467. PMID 37152312.
  11. ^ a b Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase". PLOS ONE. 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.
  12. ^ Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, et al. (March 2018). "Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques". PLOS Medicine. 15 (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946. PMID 29584730.
  13. ^ Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". The Journal of Antimicrobial Chemotherapy. 64 (4): 741–746. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.
  14. ^ Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com.
  15. ^ Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. (August 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy. 62 (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.
  16. ^ "MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza". BioSpace. Retrieved 5 May 2020.
  17. ^ Lumby CK, Zhao L, Oporto M, Best T, Tutill H, Shah D, et al. (October 2020). "Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child". Clinical Infectious Diseases. 71 (7): e191–e194. doi:10.1093/cid/ciaa023. PMID 32124919.
  18. ^ Hayden FG, Shindo N (April 2019). "Influenza virus polymerase inhibitors in clinical development". Current Opinion in Infectious Diseases. 32 (2): 176–186. doi:10.1097/QCO.0000000000000532. PMC 6416007. PMID 30724789.  
  19. ^ 条件付き承認で普及に足かせ 富山化学インフル薬の"無念" [Conditional approval hinders popularization Toyama chemical flu drug's "disappointment"] (in Japanese). 25 February 2014. Retrieved 25 February 2014.
  20. ^ "تعرف على علاج كورونا المطروح بالصيدليات المصرية وسعره ومدى نجاعته" [Learn about the Corona treatment offered in Egyptian pharmacies, its price, and its efficacy]. Al Jazeera. 11 March 2021. from the original on 23 December 2021. Retrieved 21 January 2022.
  21. ^ "A kórházakat tehermentesítheti az egyforintos koronavírus-gyógyszer" [Hospitals can be relieved of the one-forint coronavirus medicine]. telex (in Hungarian). 11 March 2021. Retrieved 30 March 2021.
  22. ^ "Korona virus: Koji se lekovi protiv Kovida-19 koriste u Srbiji" [Corona virus: What anti-Covid-19 drugs are used in Serbia]. 22 November 2021.
  23. ^ "EVA Pharma Announces Availability of Antiviral Avipiravir® Tablets in Egyptian Pharmacies". EVA Pharma. from the original on 21 January 2022. Retrieved 21 January 2022.
  24. ^ "'FabiFlu is the most economical COVID-19 treatment option': Glenmark's reply to Centre on alleged 'overpricing'". DNA India. 21 July 2020. Retrieved 22 July 2020.
  25. ^ "Favipira - Tablet - 200 mg - Beacon Pharmaceuticals Ltd. - Indications, Pharmacology, Dosage, Side Effects & other Generic Info". Medex. Retrieved 22 July 2020.
  26. ^ "Broad-Spectrum Oral Antiviral Sales Surge for COVID-19 Treatment". www.precisionvaccinations.com. Retrieved 6 November 2021.
  27. ^ . Appili Therapeutics. Archived from the original on 6 November 2021. Retrieved 6 November 2021.
  28. ^ . 8 July 2020. Archived from the original on 5 December 2023. Retrieved 11 June 2023 – via in.reuters.com.
  29. ^ "Russia approves R-Pharm's Coronavir for Covid-19 treatment". Pharmaceutical Technology. 9 July 2020. Retrieved 21 July 2020.
  30. ^ Reuters Staff (18 September 2020). "Russia approves first COVID-19 prescription drug for sale in pharmacies". Reuters (in French). Retrieved 20 September 2020.[dead link]
  31. ^ Ueda M, Tanimoto T, Murayama A, Ozaki A, Kami M (March 2022). "Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir". Clinical Pharmacology and Therapeutics. 111 (3): 545–547. doi:10.1002/cpt.2251. PMC 8251038. PMID 33882157.
  32. ^ "Russia approves first COVID-19 prescription drug for sale in pharmacies". Reuters. 18 September 2020. Retrieved 20 May 2021.
  33. ^ Pulla P (25 November 2020). "Is Favipiravir Good for COVID-19? Clinical Trial Says No, Press Release Says Yes". The Wire Science. Retrieved 20 May 2021.
  34. ^ Wipatayotin A (8 August 2021). "More patients to be given Favipiravir". The Bangkok Post. Retrieved 29 November 2021.
  35. ^ Vaidyanathan G (November 2020). "Scientists criticize use of unproven COVID drugs in India". Nature. 587 (7833): 187–188. Bibcode:2020Natur.587..187V. doi:10.1038/d41586-020-03105-7. PMID 33169025. S2CID 226295778.
  36. ^ Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P (September 2020). "Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis". Virology Journal. 17 (1): 141. doi:10.1186/s12985-020-01412-z. PMC 7512218. PMID 32972430.
  37. ^ Korula P, Alexander H, John JS, Kirubakaran R, Singh B, Tharyan P, et al. (Cochrane Infectious Diseases Group) (February 2024). "Favipiravir for treating COVID-19". The Cochrane Database of Systematic Reviews. 2 (2): CD015219. doi:10.1002/14651858.CD015219.pub2. PMC 10840071. PMID 38314855.
  38. ^ "Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial". PRINCIPLE Trial. 8 April 2021. Led by University of Oxford researchers, PRINCIPLE is one of the UK Government's national priority platform trials for COVID-19 treatments and was set-up with the intention that drugs shown to have a clinical benefit could be rapidly introduced into routine NHS care.
  39. ^ Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology. 95 (Pt 8): 1619–1624. doi:10.1099/vir.0.067199-0. PMID 24795448.
  40. ^ Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (May 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research. 105: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
  41. ^ Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (April 2014). "Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model". Antiviral Research. 104: 153–155. doi:10.1016/j.antiviral.2014.01.012. PMID 24462697.
  42. ^ "First French Ebola patient leaves hospital". Reuters. 4 October 2016.
  43. ^ "Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea". AllAfrica – All the Time. Retrieved 28 December 2014.
  44. ^ "Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea". CROIconference.org. 24 February 2015. Retrieved 17 March 2016.
  45. ^ Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, et al. (March 2016). "Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea". PLOS Medicine. 13 (3): e1001967. doi:10.1371/journal.pmed.1001967. PMC 4773183. PMID 26930627.
  46. ^ Fink S (4 February 2015). "Ebola Drug Aids Some in a Study in West Africa". The New York Times.
  47. ^ Cohen J (26 February 2015). "Results from encouraging Ebola trial scrutinized". Science. doi:10.1126/science.aaa7912. Retrieved 21 January 2016.
  48. ^ Banerjee S, Gupta N, Kodan P, Mittal A, Ray Y, Nischal N, et al. (February 2019). "Nipah virus disease: A rare and intractable disease". Intractable & Rare Diseases Research. 8 (1): 1–8. doi:10.5582/irdr.2018.01130. PMC 6409114. PMID 30881850.
  49. ^ Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, et al. (May 2018). "Favipiravir (T-705) protects against Nipah virus infection in the hamster model". Scientific Reports. 8 (1): 7604. Bibcode:2018NatSR...8.7604D. doi:10.1038/s41598-018-25780-3. PMC 5954062. PMID 29765101.
  50. ^ Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. (June 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research. 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMC 7127082. PMID 19428599.
  51. ^ Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". Antiviral Research. 100 (2): 446–454. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.
  52. ^ Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). "Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever". PLOS Neglected Tropical Diseases. 8 (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.
  53. ^ Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". Current Treatment Options in Infectious Diseases. 8 (3): 208–211. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.
  54. ^ Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". The Journal of Infectious Diseases. 213 (8): 1253–1261. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.
  55. ^ Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, et al. (January 2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1410–1414. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.
  56. ^ Antonov L (2020). "Favipiravir tautomerism: a theoretical insight". Theoretical Chemistry Accounts. 139 (8): 145. doi:10.1007/s00214-020-02656-2. PMC 7415411. PMID 32834770.
  57. ^ Deneva V, Slavova S, Kumanova A, Vassilev N, Nedeltcheva-Antonova D, Antonov L (December 2022). "Favipiravir-Tautomeric and Complexation Properties in Solution". Pharmaceuticals. 16 (1): 45. doi:10.3390/ph16010045. PMC 9864296. PMID 36678542.

External links edit

 
Scholia has a profile for favipiravir (Q16934561).
  • "Favipiravir". Drug Information Portal. U.S. National Library of Medicine.

April 11, 2024
favipiravir, help, expand, this, article, with, text, translated, from, corresponding, article, german, march, 2021, click, show, important, translation, instructions, view, machine, translated, version, german, article, machine, translation, like, deepl, goog. You can help expand this article with text translated from the corresponding article in German March 2021 Click show for important translation instructions View a machine translated version of the German article Machine translation like DeepL or Google Translate is a useful starting point for translations but translators must revise errors as necessary and confirm that the translation is accurate rather than simply copy pasting machine translated text into the English Wikipedia Consider adding a topic to this template there are already 9 093 articles in the main category and specifying topic will aid in categorization Do not translate text that appears unreliable or low quality If possible verify the text with references provided in the foreign language article You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation A model attribution edit summary is Content in this edit is translated from the existing German Wikipedia article at de Favipiravir see its history for attribution You should also add the template Translated de Favipiravir to the talk page For more guidance see Wikipedia Translation Favipiravir sold under the brand name Avigan among others 3 is an antiviral medication used to treat influenza in Japan 4 It is also being studied to treat a number of other viral infections including SARS CoV 2 4 Like the experimental antiviral drugs T 1105 and T 1106 it is a pyrazinecarboxamide derivative 5 FavipiravirClinical dataTrade namesAvigan アビガン Abigan Avifavir 1 Areplivir 2 othersOther namesT 705 favipira favilavirRoutes ofadministrationBy mouthATC codeJ05AX27 WHO Legal statusLegal statusIn general Prescription only IdentifiersIUPAC name 6 fluoro 3 hydroxypyrazine 2 carboxamideCAS Number259793 96 9PubChem CID492405DrugBankDB12466ChemSpider431002UNIIEW5GL2X7E0KEGGD09537ChEBICHEBI 134722ChEMBLChEMBL221722CompTox Dashboard EPA DTXSID60948878Chemical and physical dataFormulaC 5H 4F N 3O 2Molar mass157 104 g mol 13D model JSmol Interactive imageSMILES C1 C N C C O N1 C O N FInChI InChI 1S C5H4FN3O2 c6 2 1 8 5 11 3 9 2 4 7 10 h1H H2 7 10 H 8 11 Key ZCGNOVWYSGBHAU UHFFFAOYSA NIt is being developed and manufactured by Toyama Chemical a subsidiary of Fujifilm and was approved for medical use in Japan in 2014 6 In 2016 Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Co 7 It became a generic drug in 2019 citation needed Contents 1 Medical use 2 Side effects 3 Mechanism of action 4 Society and culture 4 1 Legal status 4 2 Brand names 4 3 Use in Russia 5 Research 5 1 COVID 19 5 2 Ebola 5 3 Nipah 5 4 Other 5 5 Tautomerism 6 References 7 External linksMedical use editFavipiravir has been approved to treat influenza in Japan 6 It is however only indicated for novel influenza strains that cause more severe disease rather than seasonal influenza 6 8 As of 2020 the probability of resistance developing appears low 6 Side effects editThere is evidence that use during pregnancy may result in harm to the baby 6 Teratogenic and embryotoxic effects were shown on four animal species 6 9 In one case report a 6 month old infant developed benign bright blue discolouration of the cornea after treatment with favipiravir which resolved after treatment cessation 10 Mechanism of action editThe mechanism of its actions is thought to be related to the selective inhibition of viral RNA dependent RNA polymerase 11 medical citation needed Favipiravir is a prodrug that is metabolized to its active form favipiravir ribofuranosyl 5 triphosphate favipiravir RTP available in both oral and intravenous formulations 12 13 In 2014 favipiravir was approved in Japan for stockpiling against influenza pandemics 14 However favipiravir has not been shown to be effective in primary human airway cells casting doubt on its efficacy in influenza treatment 15 nbsp Favipiravir ribofuranosyl triphosphate the active form inside the bodyFavipiravir RTP is a nucleoside analogue It mimics both guanosine and adenosine for the viral RdRP Incorporating two such bases in a row stops primer extension although it is unclear how as of 2013 11 Society and culture editLegal status edit The US Department of Defense developed favipiravir in partnership with MediVector Inc as a broad spectrum antiviral and sponsored it through FDA Phase II and Phase III clinical trials where it demonstrated safety in humans and efficacy against the influenza virus 16 favipiravir remains unapproved in the UK and the USA 17 In 2014 Japan approved favipiravir for treating influenza strains unresponsive to current antivirals 18 Toyama Chemical initially hoped that favipiravir would become a new influenza medication that could replace oseltamivir brand name Tamiflu However animal experiments show the potential for teratogenic effects and the approval of production by The Ministry of Health Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan 19 Despite limited data on efficacy as of March 2021 favipiravir is widely prescribed for outpatient treatment of mild to moderate COVID 19 in Egypt 20 Hungary 21 and Serbia 22 Patients are required to sign a consent form before obtaining the drug citation needed Brand names edit nbsp Favipiravir 800 mg tablets from IndiaFavipiravir is sold under the brand names Avigan アビガン Abigan Avifavir 1 Avipiravir 23 Areplivir 2 FabiFlu 24 Favipira 25 Reeqonus 26 27 and Qifenda Use in Russia edit Coronavir is the brand name of favipiravir used in Russia where it is approved for the treatment of COVID 19 It is produced and sold by R Pharm 28 29 Coronavir was approved for use in Russia in hospitals in July 2020 and in September 2020 it received approval for prescription sales for outpatient use 30 Research editCOVID 19 edit See also Coronavirus disease 2019 Research and COVID 19 drug repurposing research Favipiravir Favipiravir as an antiviral drug has been authorized for treating COVID 19 in several countries including Japan Russia Serbia Turkey India and Thailand under emergency provisions 31 32 33 34 A rapid meta review in September 2020 analyzing four studies noted that the drug led to clinical and radiological improvements however no reduction in mortality or differences in oxygen support requirement were observed and more rigorous studies were sought 35 36 A Cochrane Systematic review published in Feb 2024 noted that there is actually no real benefit with Favipiravir in treating Covid 19 in terms of mortality benefits or admission to mechanical ventillation or hospitalisation and it may not make any difference in adverse effects or serious adverse effects 37 As of May 2021 update large cohort clinical trials are underway 38 Ebola edit Research in 2014 suggested that favipiravir may have efficacy against Ebola based on studies in mouse models efficacy in humans was unaddressed 39 40 41 During the 2014 West Africa Ebola virus outbreak a French nurse who contracted Ebola while volunteering for Medecins Sans Frontieres MSF in Liberia reportedly recovered after receiving a course of favipiravir 42 A clinical trial investigating the use of favipiravir against Ebola virus disease began in Gueckedou Guinea in December 2014 43 Preliminary results presented in 2016 at the Conference on Retroviruses and Opportunistic Infections CROI later published showed a decrease in mortality in patients with low to moderate levels of virus in blood but no effect on patients with high levels the group at a higher risk of death 44 45 46 The trial design was concomitantly criticised for using only historical controls 47 Nipah edit Nipah virus is a causative agent of outbreaks of encephalitis with pneumonia and has a high case fatality rate The first outbreak occurred in Malaysia Singapore related to contact with pigs in slaughterhouses and an outbreak in Philippines related to slaughter of horses most other outbreaks have affected India and Bangladesh in Bangladesh outbreaks are often associated with consumption of raw date palm sap contaminated by saliva and urine of fruit bats 48 In a study published in the Scientific Reports Syrian hamster model for Nipah virus infection was used which closely mirrors most aspects of human disease such as widespread vasculitis pneumonia and encephalitis The hamsters were infected with a lethal dose of 104 PFU NiV M via the intraperitoneal i p route similar to previous studies and treatment was initiated immediately after infection Favipiravir was administered twice daily via the peroral p o route for 14 days The treated hamsters displayed 100 survival and no obvious morbidity after lethal NiV challenge whereas all the control cases died of severe disease 49 Other edit In experiments in animals favipiravir has shown activity against West Nile virus yellow fever virus foot and mouth disease virus as well as other flaviviruses arenaviruses bunyaviruses and alphaviruses 50 Activity against enteroviruses 51 and Rift Valley fever virus has also been demonstrated 52 Favipiravir has showed limited efficacy against Zika virus in animal studies but was less effective than other antivirals such as MK 608 53 The agent has also shown some efficacy against rabies 54 and has been used experimentally in some humans infected with the virus 55 Tautomerism edit The possible tautomerism of favipiravir has been investigated computationally 56 and experimentally 57 It was found that the enol like form was substantially more stable in organic solvents than the keto like form meaning that Favipiravir likely exists almost exclusively in the enol like form In aqueous solution the keto like tautomer is substantially stabilized due to the specific interaction with the water molecules Upon protonation the keto form is switched on citation needed nbsp Enol like tautomeric form nbsp Keto like tautomeric formReferences edit a b Avifavir Russian drug reference Medum ru a b Arelpivir Russian drug reference Medum ru Glenmark launches Covid 19 drug FabiFlu priced at Rs 103 per tablet Business Standard India Press Trust of India 20 June 2020 a b Du YX Chen XP August 2020 Favipiravir Pharmacokinetics and Concerns About Clinical Trials for 2019 nCoV Infection Clinical Pharmacology and Therapeutics 108 2 242 247 doi 10 1002 cpt 1844 PMID 32246834 Furuta Y Takahashi K Shiraki K Sakamoto K Smee DF Barnard DL et al June 2009 T 705 favipiravir and related compounds Novel broad spectrum inhibitors of RNA viral infections Antiviral Research 82 3 95 102 doi 10 1016 j antiviral 2009 02 198 PMC 7127082 PMID 19428599 a b c d e f Shiraki K Daikoku T May 2020 Favipiravir an anti influenza drug against life threatening RNA virus infections Pharmacology amp Therapeutics 209 107512 doi 10 1016 j pharmthera 2020 107512 PMC 7102570 PMID 32097670 EJ Lane 22 June 2016 Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals Fierce Pharma Retrieved 20 April 2020 Information of Avigan Tablet in relation to Covid 19 FUJIFILM Toyama Chemical Co Ltd Pilkington V Pepperrell T Hill A April 2020 A review of the safety of favipiravir a potential treatment in the COVID 19 pandemic Journal of Virus Eradication 6 2 45 51 doi 10 1016 S2055 6640 20 30016 9 PMC 7331506 PMID 32405421 Jiravisitkul P Thonginnetra S Wongvisavavit R 2023 Case report Favipiravir induced bluish corneal discoloration in infant with COVID 19 Frontiers in Pediatrics 11 1154814 doi 10 3389 fped 2023 1154814 PMC 10154467 PMID 37152312 a b Jin Z Smith LK Rajwanshi VK Kim B Deval J 2013 The ambiguous base pairing and high substrate efficiency of T 705 Favipiravir Ribofuranosyl 5 triphosphate towards influenza A virus polymerase PLOS ONE 8 7 e68347 Bibcode 2013PLoSO 868347J doi 10 1371 journal pone 0068347 PMC 3707847 PMID 23874596 Guedj J Piorkowski G Jacquot F Madelain V Nguyen TH Rodallec A et al March 2018 Antiviral efficacy of favipiravir against Ebola virus A translational study in cynomolgus macaques PLOS Medicine 15 3 e1002535 doi 10 1371 journal pmed 1002535 PMC 5870946 PMID 29584730 Smee DF Hurst BL Egawa H Takahashi K Kadota T Furuta Y October 2009 Intracellular metabolism of favipiravir T 705 in uninfected and influenza A H5N1 virus infected cells The Journal of Antimicrobial Chemotherapy 64 4 741 746 doi 10 1093 jac dkp274 PMC 2740635 PMID 19643775 Koons C 7 August 2014 Ebola Drug From Japan May Emerge Among Key Candidates Bloomberg com Yoon JJ Toots M Lee S Lee ME Ludeke B Luczo JM et al August 2018 Orally Efficacious Broad Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses Antimicrobial Agents and Chemotherapy 62 8 e00766 18 doi 10 1128 AAC 00766 18 PMC 6105843 PMID 29891600 MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza BioSpace Retrieved 5 May 2020 Lumby CK Zhao L Oporto M Best T Tutill H Shah D et al October 2020 Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child Clinical Infectious Diseases 71 7 e191 e194 doi 10 1093 cid ciaa023 PMID 32124919 Hayden FG Shindo N April 2019 Influenza virus polymerase inhibitors in clinical development Current Opinion in Infectious Diseases 32 2 176 186 doi 10 1097 QCO 0000000000000532 PMC 6416007 PMID 30724789 nbsp 条件付き承認で普及に足かせ 富山化学インフル薬の 無念 Conditional approval hinders popularization Toyama chemical flu drug s disappointment in Japanese 25 February 2014 Retrieved 25 February 2014 تعرف على علاج كورونا المطروح بالصيدليات المصرية وسعره ومدى نجاعته Learn about the Corona treatment offered in Egyptian pharmacies its price and its efficacy Al Jazeera 11 March 2021 Archived from the original on 23 December 2021 Retrieved 21 January 2022 A korhazakat tehermentesitheti az egyforintos koronavirus gyogyszer Hospitals can be relieved of the one forint coronavirus medicine telex in Hungarian 11 March 2021 Retrieved 30 March 2021 Korona virus Koji se lekovi protiv Kovida 19 koriste u Srbiji Corona virus What anti Covid 19 drugs are used in Serbia 22 November 2021 EVA Pharma Announces Availability of Antiviral Avipiravir Tablets in Egyptian Pharmacies EVA Pharma Archived from the original on 21 January 2022 Retrieved 21 January 2022 FabiFlu is the most economical COVID 19 treatment option Glenmark s reply to Centre on alleged overpricing DNA India 21 July 2020 Retrieved 22 July 2020 Favipira Tablet 200 mg Beacon Pharmaceuticals Ltd Indications Pharmacology Dosage Side Effects amp other Generic Info Medex Retrieved 22 July 2020 Broad Spectrum Oral Antiviral Sales Surge for COVID 19 Treatment www precisionvaccinations com Retrieved 6 November 2021 Favipiravir Appili Therapeutics Archived from the original on 6 November 2021 Retrieved 6 November 2021 Russian firm gets approval for drug said to block coronavirus replication 8 July 2020 Archived from the original on 5 December 2023 Retrieved 11 June 2023 via in reuters com Russia approves R Pharm s Coronavir for Covid 19 treatment Pharmaceutical Technology 9 July 2020 Retrieved 21 July 2020 Reuters Staff 18 September 2020 Russia approves first COVID 19 prescription drug for sale in pharmacies Reuters in French Retrieved 20 September 2020 dead link Ueda M Tanimoto T Murayama A Ozaki A Kami M March 2022 Japan s Drug Regulation During the COVID 19 Pandemic Lessons From a Case Study of Favipiravir Clinical Pharmacology and Therapeutics 111 3 545 547 doi 10 1002 cpt 2251 PMC 8251038 PMID 33882157 Russia approves first COVID 19 prescription drug for sale in pharmacies Reuters 18 September 2020 Retrieved 20 May 2021 Pulla P 25 November 2020 Is Favipiravir Good for COVID 19 Clinical Trial Says No Press Release Says Yes The Wire Science Retrieved 20 May 2021 Wipatayotin A 8 August 2021 More patients to be given Favipiravir The Bangkok Post Retrieved 29 November 2021 Vaidyanathan G November 2020 Scientists criticize use of unproven COVID drugs in India Nature 587 7833 187 188 Bibcode 2020Natur 587 187V doi 10 1038 d41586 020 03105 7 PMID 33169025 S2CID 226295778 Shrestha DB Budhathoki P Khadka S Shah PB Pokharel N Rashmi P September 2020 Favipiravir versus other antiviral or standard of care for COVID 19 treatment a rapid systematic review and meta analysis Virology Journal 17 1 141 doi 10 1186 s12985 020 01412 z PMC 7512218 PMID 32972430 Korula P Alexander H John JS Kirubakaran R Singh B Tharyan P et al Cochrane Infectious Diseases Group February 2024 Favipiravir for treating COVID 19 The Cochrane Database of Systematic Reviews 2 2 CD015219 doi 10 1002 14651858 CD015219 pub2 PMC 10840071 PMID 38314855 Favipiravir to be investigated as a possible COVID 19 treatment for at home recovery in the PRINCIPLE trial PRINCIPLE Trial 8 April 2021 Led by University of Oxford researchers PRINCIPLE is one of the UK Government s national priority platform trials for COVID 19 treatments and was set up with the intention that drugs shown to have a clinical benefit could be rapidly introduced into routine NHS care Gatherer D August 2014 The 2014 Ebola virus disease outbreak in West Africa The Journal of General Virology 95 Pt 8 1619 1624 doi 10 1099 vir 0 067199 0 PMID 24795448 Oestereich L Ludtke A Wurr S Rieger T Munoz Fontela C Gunther S May 2014 Successful treatment of advanced Ebola virus infection with T 705 favipiravir in a small animal model Antiviral Research 105 17 21 doi 10 1016 j antiviral 2014 02 014 PMID 24583123 Smither SJ Eastaugh LS Steward JA Nelson M Lenk RP Lever MS April 2014 Post exposure efficacy of oral T 705 Favipiravir against inhalational Ebola virus infection in a mouse model Antiviral Research 104 153 155 doi 10 1016 j antiviral 2014 01 012 PMID 24462697 First French Ebola patient leaves hospital Reuters 4 October 2016 Guinea Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea AllAfrica All the Time Retrieved 28 December 2014 Favipiravir in Patients with Ebola Virus Disease Early Results of the JIKI trial in Guinea CROIconference org 24 February 2015 Retrieved 17 March 2016 Sissoko D Laouenan C Folkesson E M Lebing AB Beavogui AH Baize S et al March 2016 Experimental Treatment with Favipiravir for Ebola Virus Disease the JIKI Trial A Historically Controlled Single Arm Proof of Concept Trial in Guinea PLOS Medicine 13 3 e1001967 doi 10 1371 journal pmed 1001967 PMC 4773183 PMID 26930627 Fink S 4 February 2015 Ebola Drug Aids Some in a Study in West Africa The New York Times Cohen J 26 February 2015 Results from encouraging Ebola trial scrutinized Science doi 10 1126 science aaa7912 Retrieved 21 January 2016 Banerjee S Gupta N Kodan P Mittal A Ray Y Nischal N et al February 2019 Nipah virus disease A rare and intractable disease Intractable amp Rare Diseases Research 8 1 1 8 doi 10 5582 irdr 2018 01130 PMC 6409114 PMID 30881850 Dawes BE Kalveram B Ikegami T Juelich T Smith JK Zhang L et al May 2018 Favipiravir T 705 protects against Nipah virus infection in the hamster model Scientific Reports 8 1 7604 Bibcode 2018NatSR 8 7604D doi 10 1038 s41598 018 25780 3 PMC 5954062 PMID 29765101 Furuta Y Takahashi K Shiraki K Sakamoto K Smee DF Barnard DL et al June 2009 T 705 favipiravir and related compounds Novel broad spectrum inhibitors of RNA viral infections Antiviral Research 82 3 95 102 doi 10 1016 j antiviral 2009 02 198 PMC 7127082 PMID 19428599 Furuta Y Gowen BB Takahashi K Shiraki K Smee DF Barnard DL November 2013 Favipiravir T 705 a novel viral RNA polymerase inhibitor Antiviral Research 100 2 446 454 doi 10 1016 j antiviral 2013 09 015 PMC 3880838 PMID 24084488 Caroline AL Powell DS Bethel LM Oury TD Reed DS Hartman AL April 2014 Broad spectrum antiviral activity of favipiravir T 705 protection from highly lethal inhalational Rift Valley Fever PLOS Neglected Tropical Diseases 8 4 e2790 doi 10 1371 journal pntd 0002790 PMC 3983105 PMID 24722586 Mumtaz N van Kampen JJ Reusken CB Boucher CA Koopmans MP 2016 Zika Virus Where Is the Treatment Current Treatment Options in Infectious Diseases 8 3 208 211 doi 10 1007 s40506 016 0083 7 PMC 4969322 PMID 27547128 Yamada K Noguchi K Komeno T Furuta Y Nishizono A April 2016 Efficacy of Favipiravir T 705 in Rabies Postexposure Prophylaxis The Journal of Infectious Diseases 213 8 1253 1261 doi 10 1093 infdis jiv586 PMC 4799667 PMID 26655300 Murphy J Sifri CD Pruitt R Hornberger M Bonds D Blanton J et al January 2019 Human Rabies Virginia 2017 MMWR Morbidity and Mortality Weekly Report 67 5152 1410 1414 doi 10 15585 mmwr mm675152a2 PMC 6334827 PMID 30605446 Antonov L 2020 Favipiravir tautomerism a theoretical insight Theoretical Chemistry Accounts 139 8 145 doi 10 1007 s00214 020 02656 2 PMC 7415411 PMID 32834770 Deneva V Slavova S Kumanova A Vassilev N Nedeltcheva Antonova D Antonov L December 2022 Favipiravir Tautomeric and Complexation Properties in Solution Pharmaceuticals 16 1 45 doi 10 3390 ph16010045 PMC 9864296 PMID 36678542 External links edit nbsp Scholia has a profile for favipiravir Q16934561 Favipiravir Drug Information Portal U S National Library of Medicine Portals nbsp Medicine nbsp Viruses Retrieved from https en wikipedia org w index php title Favipiravir amp oldid 1216536644, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.